Leflunomide Tablet, Film Coated
Product Images NDC 70771-1491

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Leflunomide (NDC 70771-1491). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Lifesciences Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (4acbf10a 7788 4034 A153 E44366ef5124 01)

Chemical structure diagram of leflunomide, showing the arrangement of functional groups including a trifluoromethyl-substituted phenyl ring linked to a substituted isoxazole ring with an amide connection.*

FDA Label Image

Image (4acbf10a 7788 4034 A153 E44366ef5124 02)

Chemical structure of teriflunomide labeled as A77 1726, a compound related to leflunomide. The diagram shows molecular bonds and functional groups including trifluoromethyl, amide, and hydroxyl groups.*

FDA Label Image

Image (4acbf10a 7788 4034 A153 E44366ef5124 03)

A bar chart titled '% ACR 20 Responder at Endpoint' showing response percentages for three clinical trials. Trials 1 and 3 are 12 months each, Trial 2 is 6 months. The chart compares Leflunomide (L), Methotrexate (M), Placebo (P), and Sulfasalazine (S) response rates, with Leflunomide and Methotrexate generally showing higher percentages than Placebo.*

FDA Label Image

Image (4acbf10a 7788 4034 A153 E44366ef5124 04)

A line graph titled 'Trial 1 ACR Responders Over Time' showing the percentage of responders over 12 months. The x-axis represents months (0, 3, 6, 9, 12) and the y-axis shows percent responders from -10 to 70. Three lines represent PL, MTX, and LEF responders, with LEF showing the highest response rates around 50-60% over time.*

FDA Label Image

Image (4acbf10a 7788 4034 A153 E44366ef5124 05)

A bar chart titled 'Change in Sharp Score' comparing progression over three trials at different durations (6 and 12 months). The chart compares Leflunomide (L), methotrexate (M), sulfasalazine (S), and placebo (P) treatments, showing varying levels of change in Sharp Score for each group across the trials.*

FDA Label Image

Image (4acbf10a 7788 4034 A153 E44366ef5124 06)

A bar chart titled 'Change in Functional Ability Measure' showing improvement data across three trials comparing leflunomide, methotrexate, placebo, and sulfasalazine over different durations (6 to 12 months). The vertical axis represents improvement from -0.6 to 0.2. Bars indicate measured changes using the HAQ Disability Index.*

FDA Label Image

Label (4acbf10a 7788 4034 A153 E44366ef5124 07)

Leflunomide Tablets USP 10 mg film-coated tablets are shown in a prescription drug label by Zydus Lifesciences Limited. The label includes images of the tablets marked with 'II' and '57', a barcode, package size of 100 tablets, storage instructions, and manufacturer information for Cadila Healthcare Ltd., India.*

FDA Label Image

Label (4acbf10a 7788 4034 A153 E44366ef5124 08)

Leflunomide Tablets USP 20 mg film-coated tablets packaging label showing the product name, strength, dosage form, and quantity of 100 tablets. The label features images of the white, triangular tablets marked with "11" and "58." It includes storage instructions, a warning to keep out of reach of children, and manufacturer details for Cadila Healthcare Ltd., India, under the Zydus Pharmaceuticals brand. The NDC code 70771-1492-1 is visible on the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.